News

Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation,

The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial

The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia. This is said to

The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones. The

The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global

The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with

Under this arrangement, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 new bispecific combinations. The company is set to receive $36.5m in

The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system. It aims to assist GenomeFrontier’s clinical activities

The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition